

March 17, 2005

<p><i>Contact:</i> Corporate Communications Yamanouchi Pharmaceutical Co., Ltd. 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan Tel:+81-3-3244-3201 Fax:+81-3-5201-7473</p>	<p><i>Contact:</i> Corporate Communications Fujisawa Pharmaceutical Co., Ltd. 4-7, Doshomachi 3-chome, Chuo-ku, Osaka 541-8514, Japan Tel:+81-6-6206-7857 Fax:+81-6-6206-5016</p>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**FOR IMMEDIATE RELEASE**

**Astellas Pharma Inc.:  
Organization of Overseas Group Companies and Their Top Management**

Yamanouchi Pharmaceutical Co., Ltd. (“Yamanouchi”; headquarters: Tokyo; President and CEO: Toichi Takenaka) and Fujisawa Pharmaceutical Co., Ltd. (“Fujisawa”; headquarters: Osaka; President and CEO: Hatsuo Aoki) are pleased to announce the reorganization of overseas group companies of Astellas Pharma Inc. (“Astellas”), which will be created as a result of their merger on April 1, as well as their top management.

The two companies announced the chief executive officers (CEO) of the headquarters of Astellas in the US and Europe, when they announced a mid-term management plan for Astellas on November 9, 2004. The new announcement is related to organizations including R&D and manufacturing in the US and Europe.

Astellas aims at efficient and flexible group management. It will reorganize existing overseas subsidiaries of Yamanouchi and Fujisawa in order to ensure sustained increases in the corporate value as a group with a capital structure that places top priority on cash flow. In North America and Europe, group companies responsible for respective functions such as R&D, production and sales and marketing will be created under the regional headquarters to ensure the most efficient operation.


1. North America

Establishment of new organization in North America will take place on April 1, 2005. Under Astellas US Holding, Inc., a wholly-owned subsidiary of Astellas, Astellas US LLC will function as Astellas' headquarters in North America, while Astellas Pharma US, Inc. will be responsible for development and sales and marketing. Astellas Pharma Manufacturing, Inc. and Astellas Pharma Technologies, Inc. will be in charge of manufacturing, while Astellas Research Institute of America LLC will be responsible for research. All other existing business bases of Yamanouchi and Fujisawa will continue to operate under the umbrella of the holding company.

Outline of major group companies in North America

New company name	Reorganized companies	Main function	Location
Astellas US Holding, Inc.	Yamanouchi US Holding, Inc. Yamanouchi Group Holding, Inc.	Holding company	Illionis, USA
Astellas US LLC	New company (created through integration of the administrative divisions of Fujisawa Healthcare, Inc. and Yamanouchi Pharma America, Inc.)	Headquarters	Illinois, USA
Astellas Pharma US, Inc.	Fujisawa Healthcare, Inc. Yamanouchi Pharma America, Inc.	Development Sales and Marketing	Illinois, USA
Astellas Pharma Manufacturing, Inc.	New company ( spin off of Grand Island Plant of Fujisawa Healthcare, Inc.)	Manufacturing	New York, USA
Astellas Pharma Technologies, Inc.	Yamanouchi Pharma Technologies, Inc.	Manufacturing	Oklahoma, USA
Astellas Research Institute of America LLC	Fujisawa Research Institute of America, Inc.	Research	Illinois, USA
Astellas Venture Capital LLC	Yamanouchi Venture Capital, LLC	Venture capital	California, USA
Astellas Pharma Canada, Inc.	Fujisawa Canada, Inc.	Development Sales and Marketing	Ontario, Canada

Organization chart (main group companies only)



## 2. Europe


Establishment of new organization in Europe will be carried out on a step-by-step basis from April 1, 2005 according to laws of all concerned countries. The new organizational structure is expected to be completed in April 2006.

Astellas Pharma Europe Ltd. (UK) will function as the headquarters of Astellas in Europe under Astellas B.V. (The Netherlands), a holding company wholly-owned by Astellas. Astellas Pharma Europe B.V. will function as the headquarters for R&D, while the development division of Astellas Pharma GmbH (Germany) will be responsible for development in the field of transplantation. Astellas Pharma Europe B.V., Astellas Ireland Ltd., etc. will be in charge of manufacturing. In addition, companies for sales and marketing will be created in 18 countries, including the UK, Germany, France, Spain, the Netherlands, Portugal, and Russia.

### Outline of major group companies in Europe

New company name	Reorganized companies	Main function	Location
Astellas B.V.	Yamanouchi B.V. Fujisawa Holland B.V Yamanouchi Europe B.V.	Holding company	the Netherlands
Astellas Pharma Europe Ltd.	Yamanouchi U.K. Limited	Headquarters	U.K.
Astellas Pharma Europe B.V.	Yamanouchi Europe B.V.	R&D Manufacturing	the Netherlands
Astellas Pharma GmbH	Fujisawa GmbH Fujisawa Deutschland GmbH Yamanouchi Pharma GmbH	Development Sales and Marketing Manufacturing	Germany
Astellas Ireland Co., Ltd.	Fujisawa Ireland Limited Yamanouchi Ireland Co., Ltd.	Manufacturing	Ireland
Astellas Pharma S.p.A.	Yamanouchi Pharma S.p.A. Fujisawa SRL	Manufacturing Sales and Marketing	Italy

### Organization chart (main companies only)



### 3. Asia

Astellas will be the parent company of all group companies in East and Southeast Asia. Existing subsidiaries of Yamanouchi and Fujisawa in South Korea and Taiwan will merge on April 1 and in October, 2005, respectively. Companies for sales and marketing will be created in China, Hong Kong, the Philippines, Thailand, and Indonesia. Astellas Pharma China, Inc. will also be in charge of production.

#### Outline of major group companies in East and Southeast Asia

New company name	Reorganized companies	Main function
Astellas Pharma Korea, Inc.	Fujisawa Korea Limited Korea Yamanouchi Pharmaceutical Co., Ltd.	Sales and Marketing
Astellas Pharma Taiwan, Inc.	Fujisawa Taiwan Co., Ltd. Taiwan Yamanouchi Pharmaceutical Co., Ltd.	Sales and Marketing
Astellas Pharma China, Inc.	Yamanouchi Pharmaceutical (China) Co., Ltd.	Manufacturing Sales and Marketing
Astellas Pharma Hong Kong Limited	Fujisawa Pharmaceuticals (China) Company Limited	Sales and Marketing
Astellas Pharma Philippines, Inc.	Yamanouchi Philippines Inc.	Sales and Marketing
Astellas Pharma (Thailand) Co., Ltd.	Yamanouchi (Thailand) Co., Ltd.	Sales and Marketing
P.T. Astellas Pharma Indonesia	P.T. Yamanouchi Indonesia	Sales and Marketing

#### Top management assignments on April 1, 2005

Organization	Position	Name	Current position
<b>&lt;North America&gt;</b>			
Astellas US LLC	Chairman and CEO	Makoto Nishimura*	Corporate Vice President, Executive Vice President, Fujisawa Healthcare, Inc.
	CFO	Akihiko Matsubara	President of Yamanouchi Pharma America, Inc.
<b>&lt;Europe&gt;</b>			
Astellas Pharma Europe Ltd.	Chairman & CEO	Yasuo Ishii	Corporate Senior Vice President of Yamanouchi
	COO	Masao Yoshida	President, Fujisawa GmbH

\* Chairman & CEO of Astellas Pharma US, Inc. at the same time

- # # # -